Myriad Genetics Inc (MYGN)
Profitability ratios
Return on sales
| Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 14.68% | 4.32% | 0.52% | -26.04% | -18.36% | 2.49% | 14.29% | 38.72% | 33.04% | 30.31% | 27.34% | 0.02% | 1.86% | -17.35% | -11.18% | -5.77% | 5.80% | 23.14% | 25.16% | 27.38% |
| Operating profit margin | -19.61% | -30.41% | -34.53% | -38.03% | -37.79% | -24.17% | -20.82% | -16.02% | -20.02% | -20.17% | -22.51% | -28.07% | -29.72% | -51.08% | -42.69% | -36.90% | -22.53% | -3.67% | -1.76% | 0.90% |
| Pretax margin | -19.70% | -30.73% | -35.18% | -38.55% | -38.06% | -24.11% | -20.82% | -16.09% | -5.77% | -4.04% | -6.75% | -8.60% | -26.35% | -50.11% | -41.70% | -35.55% | -22.99% | -4.74% | -2.80% | 0.02% |
| Net profit margin | -19.52% | -30.61% | -35.32% | -37.51% | -35.65% | -21.13% | -16.59% | -9.42% | -2.12% | -0.98% | -3.21% | -5.22% | -19.45% | -39.92% | -33.09% | -31.77% | -19.77% | -3.27% | -1.86% | 0.55% |
The profitability ratios of Myriad Genetics Inc show a fluctuating trend over the past several quarters. The gross profit margin, which indicates the efficiency of the company in managing its production costs, has varied significantly, ranging from negative percentages to a peak of 38.72%. This suggests fluctuations in the company's ability to generate profits from its core operations.
The operating profit margin and pretax margin, which reflect the company's profitability after accounting for operating expenses and taxes, have generally been negative over the periods, indicating that the company has struggled to generate profits from its core business activities. The margins have been particularly low, with operating profit margins falling below -20% and pretax margins even lower, signaling financial challenges.
The net profit margin, which represents the company's bottom line profitability after all expenses have been deducted, also shows a consistent trend of negative margins. This indicates that after considering all costs, including interest and taxes, the company has not been able to generate significant profits, with margins ranging from -39.92% to -0.98%.
Overall, the fluctuations and consistent negative profitability margins across the periods suggest that Myriad Genetics Inc has faced challenges in maintaining profitability and controlling costs. It is important for the company to focus on improving operational efficiency and cost management to enhance its profitability in the future.
Return on investment
| Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -14.37% | -20.99% | -22.45% | -24.21% | -22.16% | -14.30% | -11.73% | -10.85% | -13.75% | -13.49% | -14.42% | -14.00% | -12.89% | -21.56% | -17.33% | -16.50% | -11.68% | -1.86% | -0.91% | 0.49% |
| Return on assets (ROA) | -14.30% | -21.13% | -22.97% | -23.88% | -20.91% | -12.50% | -9.34% | -6.38% | -1.45% | -0.65% | -2.06% | -2.60% | -8.44% | -16.85% | -13.44% | -14.20% | -10.25% | -1.66% | -0.96% | 0.29% |
| Return on total capital | -19.70% | -29.12% | -31.56% | -38.66% | -33.91% | -19.64% | -15.51% | -14.10% | -4.74% | -3.09% | -5.22% | -4.99% | -16.01% | -31.02% | -25.71% | -18.59% | -13.54% | -2.01% | -0.79% | 0.92% |
| Return on equity (ROE) | -20.96% | -30.87% | -33.62% | -40.15% | -33.76% | -17.50% | -12.64% | -8.43% | -1.86% | -0.86% | -2.81% | -3.59% | -12.72% | -25.74% | -21.35% | -21.73% | -15.33% | -2.43% | -1.42% | 0.42% |
Myriad Genetics Inc's profitability ratios, as reflected in the provided data, demonstrate a significant fluctuation over the periods indicated.
- Operating return on assets (Operating ROA) exhibited a downward trend from around -0.91% in March 2020 to approximately -24.21% in September 2023, before showing some improvement to -14.37% by June 2024.
- Return on assets (ROA) followed a similar pattern, decreasing from 0.29% in March 2020 to -23.88% in September 2023, then recovering slightly to -14.30% by June 2024.
- Return on total capital experienced a consistent decline from 0.92% in December 2019 to -38.66% in September 2023, with a minor improvement to -19.70% by June 2024.
- Return on equity (ROE) displayed a comparable downward trajectory, falling from 0.42% in December 2019 to -40.15% in September 2023, before recovering slightly to -20.96% by June 2024.
Overall, these ratios indicate that Myriad Genetics Inc has faced profitability challenges during the analyzed periods, characterized by declining returns on assets, capital, and equity. The company may need to address its operational efficiency and financial performance to enhance profitability and restore investor confidence.